KCM
ANVS icon

Knoll Capital Management’s Annovis Bio ANVS Stock Holding History

Knoll Capital Management’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14,210
Closed -$147K – 24
2022
Q3 		$147K Hold
14,210
– – 0.09% 31
2022
Q2 		$161K Hold
14,210
– – 0.09% 36
2022
Q1 		$190K Hold
14,210
– – 0.12% 38
2021
Q4 		$250K Hold
14,210
– – 0.14% 36
2021
Q3 		$451K Sell
14,210
-25,000
-64% -$1.44M 0.22% 30
2021
Q2 		$3.36M Buy
+39,210
New +$1.81M 1.75% 10

Other funds holding ANVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
WFAG
Wescott Financial Advisory Group Philadelphia, Pennsylvania $1.14B AUM 16.59% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Knoll Capital Management's ANVS Position: Q4 2022 in Review

Knoll Capital Management sold out of Annovis Bio (ANVS) in Q4 2022, closing a stake of 14,210 shares — an estimated $147K sold.

Knoll Capital Management first reported a position in ANVS in Q2 2021 and held it in 6 quarters. The position peaked at $3.36M in Q2 2021. 23 funds tracked by Wall St. Rank hold ANVS as of Q4 2022.

  • Knoll Capital Management reported no remaining Annovis Bio position as of Q4 2022 after selling out during the quarter.
  • Knoll Capital Management sold 14,210 Annovis Bio shares in Q4 2022, an estimated $147K.
  • Knoll Capital Management first reported a position in Annovis Bio in Q2 2021 and held it in 6 quarters.
  • Knoll Capital Management's Annovis Bio position peaked at $3.36M in Q2 2021.
  • 23 funds tracked by Wall St. Rank held Annovis Bio as of Q4 2022.

Based on Knoll Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.